Skip to main content
. 2023 Jan 11;3(1):100243. doi: 10.1016/j.xgen.2022.100243

Table 2.

UCLA ATLAS contributes a substantial proportion of non-European ancestry samples to global meta-analyses

Trait Abbreviation Ancestry UCLA case GBMI case Enrichment ratio
Asthma asthma EUR 3,051 101,311 1.04
AFR 289 5,051 1.97
AMR 760 4,069 6.42
EAS 308 18,549 0.57
Chronic obstructive pulmonary disease COPD EUR 2,005 51,644 1.14
AFR 187 1,978 2.77
AMR 384 1,503 7.49
EAS 208 19,044 0.32
Gout gout EUR 810 20,702 1.16
AFR 105 1,312 2.38
AMR 179 557 9.55
EAS 155 10,425 0.44
Heart failure HF EUR 1,301 28,795 1.51
AFR 174 1,367 4.26
AMR 423 1,170 12.11
EAS 144 12,665 0.38
Idiopathic pulmonary fibrosis IPF EUR 700 5,229 1
AFR 76 169 3.37
AMR 204 319 4.79
EAS 89 1,210 0.55
Cerebral artery occlusion with cerebral infarction stroke EUR 855 15,842 2.48
AFR 100 1,161 3.96
AMR 248 903 12.64
EAS 105 23,345 0.21
Venous thromboembolism VTE EUR 1,503 15,970 1.11
AFR 195 1,466 1.57
AMR 543 1,037 6.18
EAS 132 193 8.07

We show the case sample sizes across 7 traits for ATLAS and across the entire GBMI study, stratified by genetic ancestry. The last column reports the ratio of the proportion of ancestry-specific samples in ATLAS compared with the proportion of total samples from the GBMI meta-analyses.